Stemtech (STEK) Non-Current Debt (2021 - 2022)

Stemtech's (STEK) quarterly Non-Current Debt came in at $77642.0 in Q2 2022, little changed quarter-over-quarter from $77642.0 in Q1 2022.

Stemtech (STEK) Non-Current Debt (2021 - 2022) Analysis & Trends

Stemtech has disclosed Non-Current Debt across 2 years of filings, most recently posting $77642.0 for Q2 2022.

Non-Current Debt for Q2 2022 came in at $77642.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $77642.0 (changed N/A YoY), and the FY2021 annual result was $219465.0, up 1109.97% from the prior year.
Non-Current Debt came in at $77642.0 for Q2 2022 at Stemtech, roughly flat from $77642.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $276106.0 in Q3 2021 to a low of $77642.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	14.02 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	9.05 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	3.92 Bn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	1.48 Bn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	569.60 Mn
10	Stemtech	-	-	354,677.00	-

Download Data